These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 2040173)

  • 1. Hypertension as a possible complication of recombinant human erythropoietin therapy.
    Brunkhorst R; Nonnast-Daniel B; Koch KM; Frei U
    Contrib Nephrol; 1991; 88():118-25; discussion 126. PubMed ID: 2040173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse cardiovascular effects of partial correction of renal anemia by recombinant human erythropoietin.
    Frei U; Nonnast-Daniel B; Schäffer J; Koch KM
    Contrib Nephrol; 1990; 82():72-8. PubMed ID: 2093530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemodynamics in hemodialysis patients treated with recombinant human erythropoietin.
    Nonnast-Daniel B; Schäffer J; Frei U
    Contrib Nephrol; 1989; 76():283-9; discussion 290-1. PubMed ID: 2684528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of blood pressure changes during recombinant human erythropoietin therapy.
    Levin N
    Semin Nephrol; 1989 Mar; 9(1 Suppl 2):16-20. PubMed ID: 2669081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Erythropoietin and hypertension].
    Frei U; Nonnast-Daniel B; Koch KM
    Klin Wochenschr; 1988 Sep; 66(18):914-9. PubMed ID: 3054276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of recombinant human erythropoietin treatment on hemodynamic parameters in continuous ambulatory peritoneal dialysis and hemodialysis patients.
    Fernández A; Vega N; Jiménez F; Macía M; Laraudiogoitía E; Hortal L; Perdomo M; Plaza C; Rodríguez JC; Palop L
    Am J Nephrol; 1992; 12(4):207-11. PubMed ID: 1481867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular hemodynamic effects of correction of anemia of chronic renal failure with recombinant-human erythropoietin.
    Schwartz AB; Prior JE; Mintz GS; Kim KE; Kahn SB
    Transplant Proc; 1991 Apr; 23(2):1827-30. PubMed ID: 2053168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypertension following erythropoietin therapy in anemic hemodialysis patients.
    Buckner FS; Eschbach JW; Haley NR; Davidson RC; Adamson JW
    Am J Hypertens; 1990 Dec; 3(12 Pt 1):947-55. PubMed ID: 2127895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemodynamic and volume changes by recombinant human erythropoietin (rHuEPO) in the treatment of anemic hemodialysis patients.
    Hori K; Onoyama K; Iseki K; Fujimi S; Fujishima M
    Clin Nephrol; 1990 Jun; 33(6):293-8. PubMed ID: 2376091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythropoietin treatment does not compromise cardiovascular function in chronic renal failure.
    Haedersdal C; Mehlsen J; Stenver D; Nielsen B; Jeppesen L; Winther K
    Angiology; 1994 Mar; 45(3):231-4. PubMed ID: 8129205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Erythropoietin and arterial hypertension in patients with chronic renal insufficiency].
    Simon P
    Rev Med Interne; 1995; 16(6):457-61. PubMed ID: 7652230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of recombinant human erythropoietin on the anemia of chronic renal failure.
    Urabe A; Takaku F; Mizoguchi H; Kubo K; Ota K; Shimizu N; Tanaka K; Mimura N; Nihei H; Koshikawa S
    Int J Cell Cloning; 1988 May; 6(3):179-91. PubMed ID: 3397592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of hypertension induced by erythropoietin in patients on hemodialysis.
    Yamakado M; Umezu M; Nagano M; Tagawa H
    Clin Invest Med; 1991 Dec; 14(6):623-9. PubMed ID: 1794212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of renal anemia by erythropoietin substitution. The effects on the cardiovascular system.
    Radermacher J; Koch KM
    Clin Nephrol; 1995 Nov; 44 Suppl 1():S56-60. PubMed ID: 8608665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in the alpha adrenergic system and increase in blood pressure with recombinant human erythropoietin (rHuEpo) therapy for renal anemia.
    Müller R; Steffen HM; Brunner R; Saric J; Pollok M; Baldamus CA; Kaufmann W
    Clin Invest Med; 1991 Dec; 14(6):614-22. PubMed ID: 1665406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral hemodynamics, blood viscosity, and the renin-angiotensin system in hemodialysis patients under therapy with recombinant human erythropoietin.
    Steffen HM; Brunner R; Müller R; Degenhardt S; Pollok M; Lang R; Baldamus CA
    Contrib Nephrol; 1989; 76():292-8. PubMed ID: 2582783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of blood pressure in end-stage renal disease with platelet cytosolic free calcium concentration during treatment of renal anemia with recombinant human erythropoietin.
    Schiffl H
    Int J Artif Organs; 1992 Jun; 15(6):343-8. PubMed ID: 1639525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of blood rheology in the pathogenesis of hypertension of hemodialysis patients treated for renal anemia with recombinant human erythropoietin.
    Baldamus CA; Steffen AM; Brunner R; Pollok M
    Contrib Nephrol; 1990; 82():79-85. PubMed ID: 2093531
    [No Abstract]   [Full Text] [Related]  

  • 19. [Effect of recombinant human erythropoietin administration on cardiovascular system in patient with chronic renal failure: an analysis of the blood pressure upward].
    Satoh K; Ikeda Y; Kurokawa S; Kamata K; Masuda T; Kikawada R; Marumo F
    Kokyu To Junkan; 1989 Mar; 37(3):313-9. PubMed ID: 2734509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of erythropoietin on cardiovascular prognosis parameters in hemodialysis patients.
    Frank H; Heusser K; Höffken B; Huber P; Schmieder RE; Schobel HP
    Kidney Int; 2004 Aug; 66(2):832-40. PubMed ID: 15253740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.